BC Investment Management Corp Invests $768K in Exact Sciences Co

🌥️Trending News

Exact Sciences ($NASDAQ:EXAS) Co. is a corporation based in Madison, Wisconsin, and specializes in developing diagnostic testing services. It provides these services to healthcare providers, as well as individuals, enabling them to monitor their health and detect disease in its earliest stages. The company has earned acclaim for its non-invasive cancer screening methods, which have made it one of the leading providers of cancer diagnostic tests in the United States.

This is a significant investment that speaks to the company’s strong growth potential and the trust placed in its products by investors. It is a positive sign that Exact Sciences Co. can continue to provide reliable diagnostic testing services in an ever-changing healthcare landscape.

Market Price

This marked the first time BC Investment Management Corp has invested in Exact Sciences Co, and signified a strong confidence in the company’s future development potential. It is unclear what impact this investment will have on the growth of Exact Sciences Co, but it is certainly an encouraging sign for the company’s potential. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Exact Sciences. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Exact Sciences. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Exact Sciences. More…

Key Ratios Snapshot

Some of the financial key ratios for Exact Sciences are shown below. More…

Analysis

At GoodWhale, we recently performed an analysis of EXACT SCIENCES‘s wellbeing. After our assessment of the company’s financial and business aspects, we have determined that this is a high risk investment. Our Risk Rating system has revealed four risk warnings in EXACT SCIENCES’s income sheet, balance sheet, cashflow statement, and non financial areas. To gain further insight into this analysis and the risks associated with this investment, we invite you to register on our website GoodWhale.com and take a closer look at our findings. More…

Peers

The market for cancer diagnostics is highly competitive. Exact Sciences Corp, Inoviq Ltd, Myriad Genetics Inc, and BCAL Diagnostics Ltd are all major players in the industry. Each company has its own unique strengths and weaknesses, and the competition between them is fierce.

– Inoviq Ltd ($ASX:IIQ)

Inoviq Ltd has a market cap of 55.21M as of 2022. The company’s Return on Equity for the same year is -13.68%.

Inoviq Ltd is a technology company that focuses on developing innovative solutions for the mobile communications industry. The company’s products and services are designed to improve the efficiency and productivity of mobile operators and enterprises. Inoviq Ltd’s portfolio includes a wide range of products and services, such as mobile network optimization, mobile device management, and mobile application development.

– Myriad Genetics Inc ($NASDAQ:MYGN)

Myriad Genetics Incorporated is a biotechnology company that focuses on the development and commercialization of molecular diagnostic tests. The company’s tests are used for the early detection and risk assessment of various diseases, including cancer, cardiovascular disease, and Alzheimer’s disease. Myriad Genetics Incorporated is headquartered in Salt Lake City, Utah.

Summary

Exact Sciences Corporation (EXAS) has recently seen significant investment from the British Columbia Investment Management Corporation (BCIMC). Exact Sciences focuses on the early detection and prevention of various forms of cancer. Their testing platforms, including Cologuard, a non-invasive DNA screening test for colorectal cancer, have been gaining widespread recognition as reliable ways to detect cancer before it has a chance to spread.

With this new investment, Exact Sciences is well-positioned to expand their business and further develop their testing technologies. This is a promising development for investors, as the testing platforms could become a major part of the healthcare industry in the coming years.